In May of 2022 Xcelerate acquired a portfolio of patents, patents pending and technology licenses from HS Pharmaceuticals LLC, a manufacturer and distributer of dermatological products for chronic wound care, burns and drug resistant infections.

The portfolio consists of four issued and one pending U.S. patents, two issued and one pending European patents, as well as certain licensing agreements in conjunction with research developed by Cambridge University.

The acquisition of this IP portfolio represents the culmination of years of research by world renowned scientists and institutions as well as the investment of millions of dollars in development costs